AS101, un interesante fármaco multipotente
205
al tratamiento de alguno de los problemas terapéuticos en los que ha demostrado
su posible aplicación.
Referencias
1.
Kalich-‐Philosoph, L.; Roness, H.; Carmely, A.; Fishel-‐Bartal, M.; Ligumsky, H.; Paglin, S.;
Wolf, I.; Kanety, H.; Sredni, B.; Meirow, D.; (2013) “Cyclophosphamide Triggers Follicle
Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility”,
Sci.
Transl. Med
. 5, 185ra62.
2.
Brydoy, M.; Fossa, S. D.; Dahl, O.; Bjøro T.; (2007) “Gonadal dysfunction and fertility
problems in cancer survivors”;
Acta Oncol
. 46, 480-‐9.
3.
Nogueira, C. W.; Zeni, G.; Rocha, J. B.T.; (2004) “Organoselenium and organotellurium
compounds: toxicology and pharmacology”,
Chem. Rev
., 104, 6255-‐6285.
4.
Yosef, S.; Brodsky, M.; Sredni, B.; Albeck, A.; Albeck M.; (2007) “Octa-‐
O
-‐bis-‐(
R,R
)-‐Tartarate
Ditellurane (SAS) -‐ a novel bioactive organotellurium(IV) compound: synthesis,
characterization, and protease inhibitory activity”;
ChemMedChem
., 2, 1601-‐1606.
5.
Cunha, R. L.; Urano, M. E.; Chagas, J. R.; Almeida, P. C.; Bincoletto, C.; Tersariol, I. L.;
Comasseto, J. V.; (2005) “Tellurium-‐based cysteine protease inhibitors: evaluation of
novel organotellurium (IV) compounds as inhibitors of human cathepsin B”;
Bioorg. Med.
hem. Lett
., 15, 755–760.
6.
Lima, C. B.; Arrais-‐Silva, W. W.; Cunha, R. L., Giorgio, S.; (2009) “A novel organotellurium
compound (RT-‐01) as a new antileishmanial agent”,
Korean J. Parasitol
., 47, 213-‐218.
7.
(a) Kalechman, Y.; Sredni, B.; (1996) ”Differential effect of the immunomodulator AS101
on B7-‐1 and B7-‐2 costimulatory molecules: role in the antitumoral effects of AS101
”
;
J.
Immunol
., 157, 589-‐597. (b) Sredni, B., Tichler, T.; Shani, A.; Catane, R.; Kaufman, B. ;
Strassmann, G.; Albeck, M.; Kalechman, Y.; (1996) “Predominance of TH1 response in
tumor-‐bearing mice and cancer patients treated with AS101
”;
J. Natl. Cancer Inst
. 88,
1276-‐1284. (c) Kalechman, Y., Strassmann, G.; Albeck, M.; Sredni, B.; (1998)
“Upregulation by ammonium trichloro(dioxoethylene-‐O,O’-‐)tellurate (AS101) of Fas/Apo-‐
1 expression on B16 melanoma cells: implications for the antitumor effects of AS101”;
J.
Immunol
., 161, 3536-‐3542. (d) Kalechman,Y.; Gafter, U.; Gal, R.; Rushkin, G.; Yan, D.;
Albeck,
M.; Sredni,
B.; (2002) “Anti-‐IL-‐10 Therapeutic Strategy Using the
Immunomodulator AS101 in Protecting Mice from Sepsis-‐Induced Death: Dependence on
Timing of Immunomodulating Intervention”,
J. Immunol
., 169, 384-‐392.
8.
(a) Sredni, B.; Caspi, R. R.; Klein, A.; Kalechman, Y.; Danziger, Y.; Benya'akov, M.; Tamari,
T.; Shalit, F.; Albeck, M.; (1987) “A new immunomodulating compound (AS-‐101) with
potential therapeutic application”;
Nature
, 330, 173-‐176. (b) Brodsky, M.;
Halpert, G.;
Albeck, M.; Sredni, B.; (2010) “The anti-‐inflammatory effects of the tellurium redox
modulating compound, AS101, are associated with regulation of NFkappaB signaling
pathway and nitric oxide induction in macrophages”;
J. Inflamm. (Lond)
, 7, 3.
9.
Sredni, B.; (2012) “Immunomodulating tellurium compounds as anti-‐cancer agents”;
Semin. Cancer Biol
., 22, 60-‐69.
10.
(a) Sredni, B.; Weil, M.; Khomenok, G.; Lebenthal, I.; Teitz, S.; Mardor, Y.; Ram, Z.;
Orenstein, A.; Kershenovich, A.; Michowiz, S.; Cohen, Y. I.; Rappaport, Z. H.; Freidkin, I.;
Albeck, M.; Longo, D. L.; Kalechman, Y.; (2004) “Ammonium trichloro(diosoethylene-‐
O,O’
-‐
tellurate (AS101) sensitizes tumors to chemotherapy by inhibitng the tumor interleukin
10 autocrine loop”;
Cancer Res.
, 64, 1843-‐1852. (b) hayan, R.; Shpungin, S.; Malovani, H.;
Albeck, M.; Okun, E.; Nir, U.; Sredni, B.; (2007) “Novel involvement of the
immunomodulator AS101 in IL-‐10 signaling, via the tyrosine kinase Fer”,
Ann. N. Y. Acad.
Sci
., 1095, 240-‐250.
11.
(a) Daniel-‐Hoffmann, M.; Albeck, M.; Sredni, B.; Nitzan, Y.; (2009)
Arch. Microb.
, 191, 631-‐
638. (b) Daniel-‐Hoffmann, M.; Sredni, B.; Nitzan, Y.; (2012) “Bactericidal activity of the
